816 Spam-Free Article(s) Found
Sort:
Date
Filter:
All
Symbol Name Last Close Mkt Cap DailyStocks'
Rating
Our DailyStocks’ Rating System is a proprietary algorithm that combines the vote of the investor community and legendary trader Richard Dennis’ Turtle Trader System and the System Rules of the Turtle Traders Each day, we generate Buy, Sell, Uptrend or Downtrend signals for 3000 Stocks in the U.S. Markets.
Vote Now!
Friday’s Close
BMY Bristol-Myers Squibb Company $61.3 $100.03B N/A
Article Searches
Pharma Stock Roundup: PFE to Buy ARRY, RHHBY, MRK, AZN Drugs Get Regulatory Nod http://www.zacks.com/stock/news/432688/pharma-stock-roundup-pfe-to-buy-arry-rhhby-mrk-azn-drugs-get-regulatory-nod?cid=CS-ZC-FT-432688 Jun 21, 2019 - Pfizer (PFE) announces definitive deal buy Array BioPharma. Merck (MRK), Roche (RHHBY) and AstraZeneca (AZN) win approvals for new drugs/line extensions.
3 Big Biotechs Hold Growth Potential in Second Half of 2019 http://www.zacks.com/stock/news/432820/3-big-biotechs-hold-growth-potential-in-second-half-of-2019?cid=CS-ZC-FT-432820 Jun 21, 2019 - We highlight a few leading players from the biotech sector, having surpassed the same so far in 2019 and are likely to put up a good show during the second half of 2019 as well.
Zimmer taps BMY vet as CFO https://seekingalpha.com/news/3472529-zimmer-taps-bmy-vet-cfo?source=feed_news_all Jun 19, 2019 - Zimmer Biomet (NYSE:ZBH) announces that EVP and Chief Financial Officer Daniel Florin will retire, effective July 1.Suketu Upadhyay has been appointed as the new CFO and comes on from his role as SVP,
Big Drugmakers That May Tread the M&A Path After Pfizer http://www.zacks.com/stock/news/431504/big-drugmakers-that-may-tread-the-ma-path-after-pfizer?cid=CS-ZC-FT-431504 Jun 19, 2019 - There has been a flurry of M&A deal announcements this year in the drug industry. Here we discuss three big drug/biotech companies, which may make the next M&A move.
Bristol-Myers (BMY) Upgraded to Buy: What Does It Mean for the Stock? http://www.zacks.com/stock/news/431501/bristol-myers-bmy-upgraded-to-buy-what-does-it-mean-for-the-stock?cid=CS-ZC-FT-431501 Jun 19, 2019 - Bristol-Myers (BMY) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Top Analyst Reports for Broadcom, Amgen & NVIDIA http://www.zacks.com/research-daily/431127/top-analyst-reports-for-broadcom-amgen-nvidia?cid=CS-ZC-FT-431127 Jun 18, 2019 - Top Analyst Reports for Broadcom, Amgen & NVIDIA
3 Big Pharma Stocks to Buy Right Now http://www.zacks.com/stock/news/429850/3-big-pharma-stocks-to-buy-right-now?cid=CS-ZC-FT-429850 Jun 14, 2019 - These big pharma stocks all have a Zacks Rank #2 or better.
Mallinckrodt Presents Encouraging Data on Acthar Gel for RA http://www.zacks.com/stock/news/429638/mallinckrodt-presents-encouraging-data-on-acthar-gel-for-ra?cid=CS-ZC-FT-429638 Jun 14, 2019 - Mallinckrodt (MNK) reports encouraging results from a phase IV study on Acthar for RA at the EULAR.
Roche Reports Positive Data on Rituxan for Pemphigus Vulgaris http://www.zacks.com/stock/news/429338/roche-reports-positive-data-on-rituxan-for-pemphigus-vulgaris?cid=CS-ZC-FT-429338 Jun 13, 2019 - Roche (RHHBY) announces positive data on rheumatic diseases drug, Rituxan, for pemphigus vulgaris.
Roche's Rituxan Gets Priority Review for Blood Disorder http://www.zacks.com/stock/news/428757/roches-rituxan-gets-priority-review-for-blood-disorder?cid=CS-ZC-FT-428757 Jun 12, 2019 - Roche (RHHBY) gets Priority Review status from the FDA for Rituxan in children with two rare blood vessel disorders.

Pages: 123456...82

Page 1>